Health and Fitness Health and Fitness
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
Astex Pharmaceuticals to Present at Piper Jaffray Health Care Conference on November 29th
[ Tue, Nov 22nd 2011 ] - Market Wire
UnitedHealthcare to Acquire XLHealth
[ Tue, Nov 22nd 2011 ] - Market Wire
Exelixis Announces November 29th Webcast of Prese .. ation at the Piper Jaffray Health Care Conference
[ Tue, Nov 22nd 2011 ] - Market Wire
Acorda Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference
[ Tue, Nov 22nd 2011 ] - Market Wire
Comprehensive Care Corporation Signs New Multi-St .. e, Multi-Service Contract With Essence Healthcare
Mon, November 21, 2011
[ Mon, Nov 21st 2011 ] - Market Wire
Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study
[ Mon, Nov 21st 2011 ] - Market Wire
Ryan & Maniskas, LLP Announces Investigation of Pharmasset, Inc.
[ Mon, Nov 21st 2011 ] - Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Hospira, Inc.
[ Mon, Nov 21st 2011 ] - Market Wire
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pharmasset, Inc.
[ Mon, Nov 21st 2011 ] - Market Wire
Trimel Pharmaceuticals Corporation Provides CompleoTRT Phase III Update
[ Mon, Nov 21st 2011 ] - Market Wire
REVLIMID erhlt Swissmedic-Zulassung fr die Behandlung einer seltenen Blutkrebsart
[ Mon, Nov 21st 2011 ] - Market Wire
InSite Vision Reports Completion of Oral Arguments in Patent Interference Litigation
[ Mon, Nov 21st 2011 ] - Market Wire
Unilife Corporation Announces Completion of Offering of 8,250,000 Shares of Common Stock
[ Mon, Nov 21st 2011 ] - Market Wire
Hologic to Showcase 3D Mammography (Breast Tomosy .. omen's Imaging Technologies at RSNA 2011, the Lar
[ Mon, Nov 21st 2011 ] - Market Wire
Watson to Present at the 2011 Piper Jaffray Health Care Conference
[ Mon, Nov 21st 2011 ] - Market Wire
Delcath Announces Agreement With European Institu .. unch of Hepatic Chemosat Delivery System in the E
[ Mon, Nov 21st 2011 ] - Market Wire
Nephros Engages Joseph S. Cervia, M.D. as Strategic Consultant
[ Mon, Nov 21st 2011 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Inves .. t, Inc. Concerning the Sale of Pharmasset to Gile
[ Mon, Nov 21st 2011 ] - Market Wire
Medtronic CFO Gary Ellis to Speak at Piper Jaffray Healthcare Conference
[ Mon, Nov 21st 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Announces I .. eaches of Fiduciary Duty by the Board of Pharmass
[ Mon, Nov 21st 2011 ] - Market Wire
Patent Licensed Exclusively to Viral Genetics to be Granted for DCA as Cancer Treatment
[ Mon, Nov 21st 2011 ] - Market Wire
Abbott Introduces the First FDA-Approved Supplemental Blood Test for Chagas Disease
[ Mon, Nov 21st 2011 ] - Market Wire
Abiomed to Present at Piper Jaffray 23rd Annual Healthcare Conference
[ Mon, Nov 21st 2011 ] - Market Wire
Poniard Pharmaceuticals Announces Shareholders Approve Merger With ALLOZYNE
[ Mon, Nov 21st 2011 ] - Market Wire
Covidien maakt definitieve overeenkomst bekend voor overname van B'RRX Medical, Inc
[ Mon, Nov 21st 2011 ] - Market Wire
Tenet Announces Completion of Its Private Offerin .. es due 2018 and Early Tender Results of Its Tende
[ Mon, Nov 21st 2011 ] - Market Wire
CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
[ Mon, Nov 21st 2011 ] - Market Wire
Rigrodsky & Long, P.A. Announces Investigation of Pharmasset, Inc.
[ Mon, Nov 21st 2011 ] - Market Wire
Swissmedic verleent goedkeuring aan REVLIMID voor behandeling van zeldzame vorm van bloedkanker
[ Mon, Nov 21st 2011 ] - Market Wire
REVLIMID recibe la aprobacin de Swissmedic para el tratamiento de un tipo raro de cncer de sangre

REVLIMID recibe la aprobacin de Swissmedic para el tratamiento de un tipo raro de cncer de sangre


Published on 2011-11-21 08:51:15 - Market Wire
  Print publication without navigation


BOUDRY, Suiza--([ ])--Celgene International Srl, filial de Celgene Corporation, (NASDAQ: CELG) ha anunciado que REVLIMID (lenalidomida) ha recibido la aprobacin de la agencia suiza de productos teraputicos (Swissmedic) para la utilizacin en pacientes con anemia dependientes de transfusin debido a sndromes mielodisplsicos de riesgo 1 de bajo a moderado asociados con una anomala citogentica de delecin 5q con o sin anomalas citognicas adicionales.

Los sndromes mielodisplsicos son un grupo de enfermedades hematolgicas que afectan a aproximadamente 300.000 personas en todo el mundo.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources